Nanosilver in the treatment of localized cutaneous leishmaniasis caused by Leishmania major (MRHO/IR/75/ER): An in vitro and in vivo study

Daru

Volumn 17, Issue 4, 2009, Pages 285-289

  Mohebali, M ^a   Rezayat, M M ^a   Gilani, K ^b   Sarkar, S ^a   Akhoundi, B ^a   Esmaeili, J ^a   Satvat, T ^a   Elikaee, S ^c   Charehdar, S ^a   Hooshyar, H ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KASHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

BALB c mice; Leishmania major; Nanosilver

Indexed keywords

IRANIAN NANOSILVER; MEGLUMINE ANTIMONATE; NANOSILVER; SILVER DERIVATIVE; SILVER NITRATE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; GENETIC STRAIN; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; LEISHMANIA MAJOR; MACROPHAGE; MALE; MOUSE; NONHUMAN; SKIN DEFECT; SKIN LEISHMANIASIS; TREATMENT OUTCOME;

EID: 74549159757     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. World Health Organization (WHO). Control of the leishmaniasis.Technical report 793, WHO press, 1990; 50-52.
2. Diseases Management Center, Ministry of Health, Treatment and Medical Education of Iran. Annual Communicable Diseases Report.2002-2003.
3. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M.Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-Resistant Leishmania tropica parasites. PLOS Medicine,2006; 3 (4): 0001-0009
4. R) for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran, Acta Tropica, 2007; 103: 33-40
5. Khatami AR, Firooz AR, Gorouhi F, Dowlati Y. Treatment of acute old world cutaneous leishmaniasis: A systematic review of the randomized controlled trials. Journal of American Academic Dermatology, 2007; 1: 1-29
6. Hadighi R, Boucher P, Khamesipour A, Meamar AR, Roy G, Ouellette M, Mohebali M. Glucantimeresistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmanial drugs. Parasitology Research, 2007; 101 (5): 1319-1322
7. Esmaeili J, Mohebali M, Edrissian GH, Rezayat MM, Ghazi- Khansari M, Charehdar S .Evaluation of miltefosine against Leishmania major (MRHO/IR/75/ER): In vitro and In vivo studies. Acta Medica Iranica, 2008; 46 (3):191-196
8. Davidson RN. Practical guide for the treatment of leishmaniasis. Drugs, 1998; 56:1009-1018
9. Asilian A, Jalayer T, Nilforooshzadeh M, Ghassemi RL, Peto R,Wayling S .Treatment of cutaneous leishmaniasis with a four-week regimen of aminosidine ointment (Paromomycin) in Iran. Bulletin World Health Organization, 2003; 81:253-259
10. Gunawan C, Teoh WY, Marquis CP, Lifla J, Amal R. Reversible Antimicrobial Photoswittching in Nanosilver. Small, 2009; 5(3):341-344
11. Mehrbod P, Motamed N, Tabatabaian M, Soleimani Estyar R, Amini E, Shahidi M, Tavasoti- Kheiri M. In Vitro Antiviral Effect of "Nanosilver" on Influenza Virus. DARU, 2009; 17: 88-93.
12. Amini M, Nahrevanian H, Farahmand M. Pathogenicity variations of susceptibility and resistance to Leishmania major MRHO/IR/75/ER strain in BALB/c and C57BL/6 mice Iranian Journal of Parasitology, 2008; 3(4):51-59